You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

729 Results
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Jan 2021
Document
Feb 2021
Document
Feb 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Document
Mar 2021
Document
Mar 2021
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Document
Apr 2021
Document
Apr 2021

Pages